| Bioactivity | TAT-GluN2B, a synthetic peptide, is a negative control of Tat-GluN2BCTM (Neuroprotective Agent)[1]. |
| Invitro | TAT-GluN2BCTM (25 µM，培养的神经元）导致 NMDA 处理后 DAPK1 显着减少，但 TAT-GluN2B 不影响 DAPK1 水平[1]。 |
| In Vivo | TAT-GluN2BCTM (10 mg/kg，静脉注射) 在大鼠局灶性缺血的 MCAo 模型中特异性敲低缺血性脑区的 DAPK1 并减少神经元损伤，但 TAT-GluN2B 不会改变缺血性或脑组织中的 DAPK1 水平[1]. |
| Name | TAT-GluN2B |
| CAS | 1587636-62-1 |
| Sequence | Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Lys-Asn-Arg-Asn-Lys-Leu-Arg-Arg-Gln-His-Ser-Tyr |
| Shortening | YGRKKRRQRRRKKNRNKLRRQHSY |
| Formula | C137H242N62O32 |
| Molar Mass | 3269.78 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fan X, et al. Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci. 2014 Mar;17(3):471-80. |